Method for in vitro glycoengineering of antibodies

Patent metadata

Field	Value
Publication number	US-11767342-B2
Application number	US-201916447110-A
Country	US
Kind code	B2
Filing date	Jun 20, 2019
Priority date	Dec 21, 2016
Publication date	Sep 26, 2023
Grant date	Sep 26, 2023

Abstract

Herein is reported a method for the enzymatic production of an antibody with a modified glycosylation in the Fc-region comprising the steps of incubating the antibody light chain affinity ligand-bound monoclonal antibody with a glycosylation in the Fc-region with a first enzyme for a time sufficient and under conditions suitable to modify the glycosylation of the Fc-region, recovering the antibody from the antibody light chain affinity ligand, incubating the recovered antibody in solution with a second enzyme for a time sufficient and under conditions suitable to modify the glycosylation of the Fc-region to a defined form, separating the antibody with the modified glycosylation in the Fc-region from the second enzyme in a cation exchange chromatography, and thereby producing the antibody with a modified glycosylation in the Fc-region.

First claim

What is claimed is:

1. A method for the enzymatic production of a glycosylation modified antibody comprising
a) incubating a first antibody affinity ligand-bound monoclonal antibody with a glycosylation at an N-glycosylation site with a first enzyme and a first activated sugar residue for a time sufficient and under conditions suitable to modify the glycosylation at the N-glycosylation site thereby producing a first modified antibody,
(b) recovering the first modified antibody from the antibody affinity ligand,
(c) incubating the recovered first modified antibody in solution with a second enzyme and a second activated sugar residue for a time sufficient and under conditions suitable to modify the glycosylation at the N-glycosylation site of the first modified antibody thereby producing the glycosylation modified antibody, and
(d) separating the glycosylation modified antibody from the second enzyme in a cation exchange chromatography, wherein the first enzyme is a galactosyltransferase and the second enzyme is a sialyltransferase.

2. The method of claim 1 , wherein the cation exchange chromatography material has a matrix of cross-linked agarose with sulfopropyl cation exchange groups.

3. The method of claim 1 , wherein the galactosyltransferase is β4GalT1.

4. The method of claim 1 , wherein the sialyltransferase is ST6.

5. The method of claim 1 , wherein the step of separating comprising,
i) applying a solution comprising the first enzyme and second enzyme and the glycosylation modified antibody to a cation exchange chromatography material,
ii) washing the cation exchange chromatography material with a wash solution to remove unbound compounds from the cation exchange chromatography material but without eluting the glycosylation modified antibody,
iii) applying a first solution to the cation exchange chromatography material and thereby eluting the first enzyme from the cation exchange chromatography material,
iv) applying a second solution to the cation exchange chromatography material and thereby eluting the glycosylation modified antibody from the cation exchange chromatography material, and
v) applying a linear gradient to the cation exchange chromatography material and thereby eluting the second enzyme from the cation exchange chromatography material.

6. The method of claim 5 , wherein
the solution of step i) is a 2-(N-morpholino)ethanesulfonic acid (MES) buffered solution with a pH value from pH 5.0 to pH 6.5,
the wash solution of step ii) is a 2-(N-morpholino)ethanesulfonic acid (MES) buffered solution with a pH value from pH 5.0 to pH 6.5,
the first solution of step iii) is a tris(hydroxymethyl)aminomethane (TRIS) buffered solution with a pH value from pH 6.6 to pH 8.0,
the second solution of step iv) is a 2-(N-morpholino)ethanesulfonic acid (MES) buffered solution with a pH value from pH 5.0 to pH 6.5 comprising 75 mM to 125 mM sodium chloride (NaCl),
the linear gradient is from the solution of step iv) to a 2-(N-morpholino)ethanesulfonic acid (MES) buffered solution with a pH value from pH 5.0 to pH 6.5 comprising 750 mM to 1250 mM sodium chloride (NaCl).

7. A method for producing a glycosylation modified antibody comprising:
applying a solution comprising an antibody with a glycosylation at an N-glycosylation site to an antibody affinity ligand bound to a solid phase,
enzymatically modifying a glycosylation at an N-glycosylation site of the antibody by applying a solution comprising a first glycosylation modifying enzyme and a first activated sugar residue for a time sufficient and under conditions suitable for enzymatic modification to the ligand-bound antibody thereby producing a first modified antibody,
recovering the first modified antibody from the antibody affinity ligand, and
incubating the recovered first modified antibody in solution with a second enzyme and a second activated sugar residue for a time sufficient and under conditions, wherein the first enzyme is a galactosyltransferase and the second enzyme is a sialyltransferase.

8. The method of claim 1 , wherein the antibody is a bivalent monospecific antibody or a bivalent bispecific antibody or an antibody Fab fragment.

9. The method of claim 1 , wherein the antibody is a chimeric or humanized or human antibody.

10. The method of claim 7 , wherein the antibody is a monoclonal antibody.

11. The method of claim 1 , wherein the antibody is an antibody of the human IgG1 or IgG4 subclass.

12. The method of claim 1 , wherein the N-glycosylation site is an Fc-region N-glycosylation site at asparagine residue 297 (numbering according to Kabat) or is a Fab region N-glycosylation site.

13. The method of claim 1 further comprising the steps of:
recovering the first enzyme used in incubating step a) thereby producing a recycled first enzyme;
recovering the second enzyme used in incubating step c) thereby producing a recycled second enzyme; and
incubating a second antibody that has a glycosylation at an N-glycosylation site with at least one of the recycled first enzyme or the recycled second enzyme for a time sufficient and under conditions suitable to modify the glycosylation at the N-glycosylation site of the second antibody.

14. The method of claim 1 further comprising the steps of:
recovering the first enzyme used in incubating step a) thereby producing a recycled first enzyme;
recovering the second enzyme used in incubating step c) thereby producing a recycled second enzyme; and
repeating incubating step a) with the recycled first enzyme, and repeating incubating step c) with the recycled second enzyme.

15. The method of claim 1 , wherein the step of separating comprising,
i) applying a solution comprising the second enzyme and the glycosylation modified antibody to a cation exchange chromatography material,
ii) applying an eluting solution to the cation exchange chromatography material and thereby eluting the glycosylation modified antibody from the cation exchange chromatography material, and
iii) applying a linear gradient to the cation exchange chromatography material and thereby eluting the second enzyme from the cation exchange chromatography material.

16. The method of claim 1 , wherein the antibody affinity ligand is a light chain affinity ligand.

17. The method of claim 1 , wherein the antibody affinity ligand is an Fc region affinity ligand.

18. A method for the enzymatic production of an antibody with a modified glycosylation at an N-glycosylation site, comprising
a) incubating the antibody light chain affinity ligand-bound monoclonal antibody with a glycosylation at an N-glycosylation site with a first enzyme and a first activated sugar residue for a time sufficient and under conditions suitable to modify the glycosylation at the N-glycosylation site thereby producing a first modified antibody,
b) recovering the first enzyme and producing thereby a recycled first enzyme,
c) recovering the first modified antibody from the antibody light chain affinity ligand,
d) incubating the recovered first modified antibody in solution with a second enzyme and a second activated sugar residue for a time sufficient and under conditions suitable to modify the glycosylation at the N-glycosylation site of the first modified antibody thereby producing the glycosylation modified antibody;
e) separating the glycosylation modified antibody from the second enzyme in a cation exchange chromatography, optionally recovering the second enzyme and producing thereby a recycled second enzyme, and
f) repeating step a) with the first recycled enzyme of step b) at least

Assignees

• Hoffmann La Roche

Inventors

• Dams Thomas
• Falkenstein Roberto
• Malik Sebastian
• Grunert Ingrid
• Thomann Marco
• Freiherr Von Roman Matthias
• Walch Heiko

Classifications

• A61K2039/505

  comprising antibodies · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07K1/18 Primary

  Ion-exchange chromatography · CPC title

• C07K16/18

  against material from animals or humans · CPC title